Blog · Finance metrics and formulas · Pharmaceuticals
Choose pharmaceutical ratios for product margin, research spending and working capital. A worked US company example connects gross-to-net deductions, operating costs and inventory days without inventing an industry target.
Pharmaceutical industry financial ratios connect product economics, research spending and cash tied up in inventory and customer balances. Use net revenue consistently, separate commercial activity from development activity, and read the ratios beside the product and program details that produced them.
A high gross margin is not the same as high operating profitability after research and selling expenses. A rising R&D percentage is not proof that research spending increased. The useful review explains each numerator and denominator before comparing the result with a prior period or a supplied peer.
| Question | Measure | Prepared rows needed |
|---|---|---|
| What remains after product cost? | Gross profit / Net revenue | Net revenue and matched cost of sales |
| What remains after operating expenses? | Operating income / Net revenue | Gross profit, R&D and other operating expenses |
| How much revenue supports research spending? | R&D expense / Net revenue | Recognized R&D expense and net revenue |
| How much inventory is supporting the business? | Average inventory / Cost of sales × 365 | Comparable inventory balances and cost of sales |
| How long is cash tied up after billing? | Average trade receivables / Credit revenue × 365 | Trade receivables and credit revenue |
The SEC's financial statement guide defines operating margin using income from operations divided by net revenue. Use that common base to connect the expense ratios, while keeping general formula detail with the financial ratios guide.
Research activity needs an additional view by program stage. The FDA's drug development process distinguishes discovery, preclinical research, clinical research, review and monitoring after approval. Those stages are useful context for a spending review; a financial ratio does not establish clinical progress or the probability of approval.
Bring the monthly income statement, revenue deduction schedule, product cost report, inventory balances, trade receivables and trade payables. Keep product, channel, accounting period and currency where they exist. The deductions schedule must tie to the recognized revenue in the income statement rather than simply listing cash payments made during the period.
This invented US commercial pharmaceutical company reports a full year in USD. All revenue is on credit. Rebates and returns below are recognized revenue deductions for that year, and all costs are on the same reporting basis.
| Revenue bridge | Amount (USD) |
|---|---|
| Gross invoiced sales | 60,000,000 |
| Less recognized rebates and related allowances | 12,000,000 |
| Less recognized returns and other revenue deductions | 3,000,000 |
| Net revenue: 60,000,000 − 12,000,000 − 3,000,000 | 45,000,000 |
Total deductions are $15,000,000: $12,000,000 + $3,000,000. Dividing by gross invoiced sales gives a 25.0% deduction rate: 15,000,000 / 60,000,000. This is the company's example, not an industry benchmark.
Do not add a cash settlement of an existing rebate liability as another revenue deduction. Reconcile the revenue entry, liability movement and cash settlement according to the company's accounting policy so the same economic amount is not counted again.
Gross margin = (Net revenue − Cost of sales) / Net revenue
R&D intensity = Recognized R&D expense / Net revenue
Operating margin = Operating income / Net revenue
| Income statement step | Calculation | Result (USD) |
|---|---|---|
| Net revenue | From the revenue bridge | 45,000,000 |
| Cost of sales | Prepared product cost report | 13,500,000 |
| Gross profit | 45,000,000 − 13,500,000 | 31,500,000 |
| R&D expense | Prepared operating expense report | 9,000,000 |
| Selling and administrative expense | Prepared operating expense report | 9,900,000 |
| Operating income | 31,500,000 − 9,000,000 − 9,900,000 | 12,600,000 |
The ratios use the net revenue from the first table. Percentages are rounded to one decimal place after calculation.
| Ratio | Calculation | Result |
|---|---|---|
| Gross margin | 31,500,000 / 45,000,000 | 70.0% |
| R&D intensity | 9,000,000 / 45,000,000 | 20.0% |
| Selling and administrative expense ratio | 9,900,000 / 45,000,000 | 22.0% |
| Operating margin | 12,600,000 / 45,000,000 | 28.0% |
The ratio check is 70.0% − 20.0% − 22.0% = 28.0%. The dollar check is $13,500,000 + $9,000,000 + $9,900,000 + $12,600,000 = $45,000,000. Both must reconcile to the same income statement scope.
Using gross invoiced sales would instead show R&D intensity of 9,000,000 / 60,000,000 = 15.0%. Spending has not changed; the denominator has. Keep the detailed gross profit margin method separate from the judgment about how research costs affect operating results.
The balance reports provide the following additional inputs. Inventory is net of the company's recorded allowances, consistently at both dates. Payables are trade balances relating to the cost base used here; cost of sales is an explicitly chosen proxy for purchases in the payables measure.
| Balance | Beginning (USD) | Ending (USD) | Average calculation (USD) |
|---|---|---|---|
| Inventory | 6,000,000 | 7,500,000 | (6,000,000 + 7,500,000) / 2 = 6,750,000 |
| Trade receivables | 7,000,000 | 8,000,000 | (7,000,000 + 8,000,000) / 2 = 7,500,000 |
| Trade payables | 3,000,000 | 3,750,000 | (3,000,000 + 3,750,000) / 2 = 3,375,000 |
| Working capital measure | Calculation | Result |
|---|---|---|
| Inventory days | 6,750,000 / 13,500,000 × 365 | 182.5 days |
| Receivable days | 7,500,000 / 45,000,000 × 365 | 60.8 days |
| Payable days, cost-of-sales proxy | 3,375,000 / 13,500,000 × 365 | 91.3 days |
| Cash conversion cycle | Unrounded receivable days + inventory days − payable days | 152.1 days |
The cycle uses unrounded components; displayed days are rounded to one decimal place. It describes the prepared balances, not an acceptable stock target. Investigate inventory by product, lot, quality status and expiration before recommending a reduction.
Change only one input: recognized revenue deductions rise by $3,000,000. Net revenue becomes $42,000,000: $45,000,000 − $3,000,000. Product costs, R&D and selling expenses stay unchanged.
Gross profit becomes $28,500,000 and operating income becomes $9,600,000. Gross margin is 28,500,000 / 42,000,000 = 67.9%; operating margin is 9,600,000 / 42,000,000 = 22.9%; and R&D intensity is 9,000,000 / 42,000,000 = 21.4%. The higher research percentage came from lower net revenue, even though research spending did not move.
Finance owns that bridge. Commercial finance owns the explanation of channel and deduction changes, research finance owns spending by program, and operations owns inventory explanations. Use industry averages for financial ratios to assess a supplied comparison without treating an unrelated product portfolio as a target.
Bring a prepared revenue bridge, product costs, research expenses and working capital balances in a file or Google Sheet. Covirage maps the columns; its tools compute and check the figures, and the external AI model explains the results with every figure traced to its rows.
Create a free Covirage account and bring a sample of your own data. Creating the account takes about a minute.
See Covirage for pharmaceutical teams for the supporting industry context.
For a commercial operating review, start with gross margin, operating margin, R&D intensity and working capital days. Keep product and channel detail underneath the totals. A company without commercial revenue needs a spending and funding review because revenue-based margins may have no meaningful denominator.
It shows a larger share of net revenue spent on research and development, but does not measure research quality or approval prospects. The ratio can rise when spending increases or when revenue falls. Review the spending amount and program stage alongside the percentage.
Use net revenue for margins and R&D intensity when that matches the prepared income statement. Reconcile gross billings through rebates, returns and other revenue deductions. A change in those deductions can move every revenue-based ratio without changing the underlying spending amounts.
Inventory days identifies how much cost is tied up relative to sales cost. It cannot determine whether specific stock is usable. Review lot-level expiration, quality status, demand and the recorded inventory allowance separately before deciding which balances require attention.